Profile Lead Compounds in Own Lab 08 Jul 2010: Promega Corporation has partnered with SignalChem Pharmaceuticals to launch a flexible and complete kinase solution for the profiling of lead compounds against kinases representative of all major families of the kinome. Through using this single platform, scientists can easily profile lead compounds in their own laboratories in a cost-effective manner with no loss in sensitivity. Promega Corp.
Recent articles:
Live-Cell, Real-Time Monitoring of cAMP Kinetics with Promega GloSensor™ Technology 04 Apr 2008: Promega Corporation announces the launch of a breakthrough cell-based biosensor technology, termed GloSensor™ Technology. The non-lytic, live-cell GloSensor cAMP Assay is the first application of the patent-pending technology, which features a genetically engineered form of firefly luciferase. Promega Corp.
New Promega Bioluminescent Assays Provide Greatest Sensitivity 21 Jan 2008: Now scientists have tools that are 100- to 1,000-fold more sensitive than existing assays for caspase-2 and -6. Promega Corporation announces the expansion of bioluminescent caspase assays with the release of Caspase-Glo® 2 and 6 Assays that will enable new insights to their physiological roles in apoptosis. Promega Corp.
Advances in Bioluminescent Assays for G-Protein-Coupled Receptors 16 Aug 2007: Bioluminescent assays are uniquely suited for high throughput screening due to their inherent high sensitivity, wide dynamic range and low susceptibility to compound interference. This poster demonstrates how bioluminescent assays provide powerful tools to investigate GPCR function and identify modulators. Promega Corp.
